Version 1
: Received: 14 October 2024 / Approved: 15 October 2024 / Online: 16 October 2024 (04:33:30 CEST)
How to cite:
Lundstrom, K. Self-Replicating Alphaviruses: From Pathogens to Therapeutic Agents. Preprints2024, 2024101186. https://doi.org/10.20944/preprints202410.1186.v1
Lundstrom, K. Self-Replicating Alphaviruses: From Pathogens to Therapeutic Agents. Preprints 2024, 2024101186. https://doi.org/10.20944/preprints202410.1186.v1
Lundstrom, K. Self-Replicating Alphaviruses: From Pathogens to Therapeutic Agents. Preprints2024, 2024101186. https://doi.org/10.20944/preprints202410.1186.v1
APA Style
Lundstrom, K. (2024). Self-Replicating Alphaviruses: From Pathogens to Therapeutic Agents. Preprints. https://doi.org/10.20944/preprints202410.1186.v1
Chicago/Turabian Style
Lundstrom, K. 2024 "Self-Replicating Alphaviruses: From Pathogens to Therapeutic Agents" Preprints. https://doi.org/10.20944/preprints202410.1186.v1
Abstract
Alphaviruses are known for being model viruses for studying cellular functions related to viral infection but also for causing epidemics in different parts of the world. More recently, alphavirus-based expression systems have demonstrated efficacy as vaccines against infectious diseases and as therapeutic applications for different cancers. The self-replicating feature of alphaviruses has provided the advantage of extremely high transgene expression of vaccine-related antigens and therapeutic anti-tumor and immunostimulatory genes, which has also permitted significantly reduced doses for prophylactic and therapeutic applications potentially reducing adverse events. Furthermore, alphaviruses have shown favorable flexibility as they can be delivered as recombinant viral particles, RNA replicons or DNA replicon-based plasmids. In the context of infectious diseases robust immune responses against the surface proteins of target agents have been observed and protection against challenges with lethal doses of infectious agents in rodents and primates. Similarly, expression of anti-tumor genes and immunostimulatory genes from alphavirus vectors has provided tumor growth inhibition, tumor regression and cure in animal cancer models. Moreover, protection against tumor challenges has been observed. In clinical settings, clinical benefits have been reported. Alphaviruses have also been considered for the treatment of neurological disorders due to their neurotrophic preference. Attention has been paid to alphavirus vector and expression system improvement. Point mutations in the non-structural alphaviral replicase genes have generated enhanced transgene expression and created temperature-sensitive expression vectors. The recently engineered trans-amplifying RNA system has facilitated vector production and enhanced the expression capacity.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
